이상반응 보고

VAERS ID	2247526
성별	남성
나이	19세
주 코드	FR
제약회사	MODERNA
로트 번호
예방접종 횟수	1
접종일	2021-07-06
발병일	2021-07-06
상태	회복

증상

• 발진(Rash)
• 혈관염(Vasculitis)

이환 중 질병

지병

기타 의료

이전 예방접종

알레르기

임상 검사

증상 상세

Skin rash (non-injection site); Vasculitides; This regulatory authority case was reported by an other health care professional and describes the occurrence of RASH (Skin rash (non-injection site)) and VASCULITIS (Vasculitides) in a 19-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.
No Medical History information was reported.
On 06-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form.
On 06-Jul-2021, the patient experienced RASH (Skin rash (non-injection site)) (seriousness criterion medically significant) and VASCULITIS (Vasculitides) (seriousness criterion medically significant).
At the time of the report, RASH (Skin rash (non-injection site)) and VASCULITIS (Vasculitides) had resolved.
The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
No concomitant medications reported.
On 06-Jul-2022: At 12 hours after administration of Moderna vaccine in Hospital, rash occurred, repeatedly for a long time.
After treatment in hospital for several months, the patient was diagnosed by the doctor to have vasculitis.
On 07-Apr-2022: It was reported that the patient received the vaccine, there was chest compression discomfort in the week, followed by urticaria like symptoms all over the body which were serious on both hands and feet, vasculitis on the limbs, blood stasis with unknown cause which occurred repeatedly and unable to recover.
The patient was being treated with antihistamine and steroids.
On 08-Apr-2022: The patient said that there was no discomfort at that time.
The last medical treatment was in December last year.
The patient has been recovered.
Company comment: This regulatory authority case concerns a 19-year-old male patient with no medical history reported, who experienced the unexpected serious event of Rash and Vasculitis (seriousness criterion medically significant) which occurred on same day after the first dose of mRNA-1273 vaccine.
It was reported that patient had chest compression and discomfort in the week, followed by urticaria like symptoms all over the body which were serious on both hands and feet, vasculitis on the limbs, blood stasis with unknown cause which occurred repeatedly and unable to recover.
The patient was being treated with antihistamine and steroids.
The benefit-risk relationship of mRNA-1273 is not affected by this report.
Event's seriousness retained as per Regulatory Authority reporting.
; Sender's Comments: This regulatory authority case concerns a 19-year-old male patient with no medical history reported, who experienced the unexpected serious event of Rash and Vasculitis (seriousness criterion medically significant) which occurred on same day after the first dose of mRNA-1273 vaccine.
It was reported that patient had chest compression and discomfort in the week, followed by urticaria like symptoms all over the body which were serious on both hands and feet, vasculitis on the limbs, blood stasis with unknown cause which occurred repeatedly and unable to recover.
The patient was being treated with antihistamine and steroids.
The benefit-risk relationship of mRNA-1273 is not affected by this report.
Event's seriousness retained as per Regulatory Authority reporting.